Printer Friendly

LA JOLLA PHARMACEUTICAL ALLOWED PATENT FOR LUPUS TREATMENT

 SAN DIEGO, July 21 /PRNewswire/ -- La Jolla Pharmaceutical Co. announced today that it received a Notice of Allowance from the U.S. Patent and Trademark Office for its Toleragen(TM) molecules to treat Systemic Lupus Erythematosus (SLE). The claims broadly cover a family of molecules to treat the potentially life-threatening kidney diseases which occurs in many lupus patients. LJP's drug candidate for lupus, LJP-394, is now moving from R&D to manufacturing scale-up and toxicology trials.
 Lupus is a disease with no adequate treatment, which afflicts more than 500,000 in the United States and Europe. LJP-394 arrests the synthesis of antibodies to double-stranded DNA, a hallmark of the disease, which are considered to be responsible for the debilitating chronic kidney disease of lupus patients. The worldwide market is estimated to exceed $1 billion.
 "The allowance of broad composition of matter claims for our lupus toleragens enables us to establish a very strong proprietary position. We expect additional applications to be allowed in the U.S., Europe and the Far East," said Joseph Stemler, president and chief executive officer.
 La Jolla Pharmaceutical was founded in 1989 to develop products based on its proprietary "Tolerance Technology(TM)" to treat antibody mediated diseases. The company is privately held and is headquartered in San Diego.
 -0- 7/21/93
 /CONTACT: Andrew Wiseman, Ph.D., of La Jolla Pharmaceutical, 619-452-6600/


CO: La Jolla Pharmaceutical Co. ST: California IN: MTC SU:

JL-BP -- SD001 -- 3731 07/21/93 08:02 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 21, 1993
Words:245
Previous Article:INDEPENDENCE BANCORP DECLARES QUARTERLY DIVIDEND
Next Article:RED LION INNS L.P. DECLARES CASH DISTRIBUTION
Topics:


Related Articles
LA JOLLA PHARMACEUTICAL'S PATENT ALLOWED
LA JOLLA PHARMACEUTICAL CO. ANNOUNCES SECOND GENERATION MOLECULE TO TREAT LUPUS
ROBERT J. TERNANSKY, Ph.D., JOINS LA JOLLA PHARMACEUTICAL TO HEAD INFLAMMATION PROGRAM
LA JOLLA PHARMACEUTICAL CO. FILES IND ON NEW DRUG FOR LUPUS
LA JOLLA PHARMACEUTICAL CO. REPORTS THIRD QUARTER 1994 RESULTS
La Jolla Pharmaceutical Awarded Third U.S. Patent For Lupus Drug
La Jolla Pharmaceutical Receives Core Technology Patents in Europe and Japan
La Jolla Pharmaceutical receives patent on stroke treatment.
La Jolla Pharmaceutical receives Riquent composition of matter patents in Europe and China.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters